FDA last week declined to review the application by ImClone Systems Inc. for C225, a treatment for colorectal cancer patients who develop progressive disease following treatment with CPT-11. The agency’s “refusal to file” letter for C225 said the data presented by the company were insufficient to evaluate the Biologics License Application for the therapy. ImClone […]
